More sales, more profits, but less dividends: Emma Walmsley’s roadmap for New GSK

3 min read | June 23, 2021 05:25 PM BST | By Kamalika Ghosh

Google News:

More sales, more profits, but less dividends: Emma Walmsley’s roadmap for New GSK — Image source: Billion Photos,Shutterstock

Recent News

Can the ASX 200 Rise as Alphabet and Tesla Rattle Wall Street? (23 Jul...

Why Is (ASX:WDS) Powering a Stronger ASX Open?

Why Are Australian Shares Set to Rise While New Zealand Falls?

Why Could the ASX Defy Wall Street as Oil Prices Surge?

Make Kalkine Media
My Trusted Source

Summary

GlaxoSmithKline plans to make sales over £33 billion by 2031.

The company plans to slash dividend payout by 30 per cent.

The new consumer healthcare segment would help it unlock New GSK’s potential

GlaxoSmithKline’s (LON:GSK) CEO Emma Walmsley has said that by 2031, the company plans to make sales of over £33 billion and increase adjusted operating profit by 10 per cent in the next half-decade. However, the company plans to slash dividend payout by 30 per cent as well.

The details are a part of Walmsley’s plans for New GSK as the company is headed for a split next year and has plans to divest the consumer healthcare division by the middle of 2022. The company is also under immense pressure from activist investor Elliot Management that has built a stake worth multi-billion-pound in the pharma company. Its profit took a hit as the company lagged much behind in the race for coronavirus vaccines to competitors like AstraZeneca (LON:AZN).

Walmsley said that except for a 20 per cent stake retained in the consumer healthcare division by New GSK, the rest would go to shareholders. It would be listed as a different entity on London Stock Exchange. New GSK would divest its remaining stake gradually.

The company said that the new consumer healthcare segment would help unlock New GSK’s potential, strengthen its balance sheet, and provide shareholders with maximum value. The outlook for New GSK’s profit growth between 2021-26 would be supported by revenue generated from new vaccines as well as specialty medicines. It would also improve the company’s operational performance.

The adjusted operating margin is expected to rise to over 30 per cent by 2026 from the current mid-20 per cent range. Cost savings realisation improved sales growth, and benefits from the sales mix from earlier announced programmes would lead to improvements to the margin.

The company revised its target for cost savings to £1 billion from £800 million, and all its restructuring plans would be completed in 2022.

Its £33 billion-sales depends on New GSK’s current pipeline. The company expects that some of its assets presently in later stages of development can generate the highest year sales worth over £20 billion.

The sales ambition has been estimated before considering revenue expected from a pipeline of assets or any other business developments. It aims for sales growth despite anticipated exclusivity loss in 2028-29 for dolutegravir.

The company also said that the remuneration committee would gradually incorporate the new ambitions and outlooks into ongoing incentive plans.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.